PATENT CLAIM ANALYSIS

Application Number: 16051913
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2018-11
Patent Classification: ["514", "230500"]

Abstract:
The present disclosure provides bicyclic heterocyclic derivatives of formula (I), which may be therapeutically useful, more particularly as bromodomain inhibitors; (I), in which R 1 , R 2 , R 3 , R 4 , L 1 , L 2 , Cy 1 , Cy 2 , X, n, and dotted line have the same meaning given in the specification, and pharmaceutically acceptable salts or pharmaceutically acceptable stereoisomers thereof that are useful in the treatment and prevention of diseases or disorders, in particular their use in diseases or disorders associated as bromodomain inhibitors. The present disclosure also provides preparation of compounds and pharmaceutical formulations comprising at least one of bicyclic heterocyclic derivatives of formula (I), together with a pharmaceutically acceptable carrier, diluent, or excipient.

Claim (Index 8):
The compound according to  claim 1 , wherein\n R 4  is alkyl, cyanoalkyl, hydroxyalkyl, or optionally substituted haloalkyl; wherein the optional substituent is hydroxy.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 96.0
- Lexical Diversity: 1.90667
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15110361', '14977508', '14900139', '14134793', '14997213']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7405104187379651
- 35 USC 102 Novelty (BERT): 0.5740516928175357
- Combined Prediction Score: 0.7238645461459221
- Mean Citation Score: 381.937524
- Max Citation Score: 439.6207
- Similarity Product: 418.94516733073584

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test